The Lancet: Preliminary results from Russian trials find that vaccine candidates led to no serious adverse events and elicit antibody response
The new paper reports the findings of two open-label, non-randomised phase 1/2 trials looking at a frozen formulation and a freeze-dried formulation of a two-part vaccine. The two-part vaccine included two adenovirus vectors – recombinant human adenovirus type 26 (rAd26-S) and recombinant human adenovirus type 5 (rAd5-S) In the phase 1 part of each trial,…
Details